Certified Researchers

Heart Valves Market Summary

According to MRFR analysis, the Heart Valves Market Size was valued at USD 9.088 Billion in 2024. The market is projected to grow from USD 10.2 Billion in 2025 to USD 32.25 Billion by 2035, registering a CAGR of 12.2% during the forecast 2025–2035. North America led the market with over 45% share, generating around USD 4.1Billion in revenue.

Key Market Trends & Highlights

The Heart Valves Market is experiencing robust growth driven by technological advancements and increasing demand for minimally invasive procedures.

North America remains the largest market for heart valves, driven by advanced healthcare infrastructure and high patient awareness.
The Asia-Pacific region is emerging as the fastest-growing market, fueled by rising healthcare investments and a growing population.
Aortic valve repair continues to dominate the market, while mitral valve repair is witnessing the fastest growth due to increasing procedural adoption.
Key market drivers include the aging population and the rising incidence of cardiovascular diseases, which are propelling demand for innovative heart valve solutions.

Market Size & Forecast

2024 Market Size	9.088 (USD Billion)
2035 Market Size	32.25 (USD Billion)
CAGR (2025 - 2035)	12.2%

Major Players

Edwards Lifesciences (US), Medtronic (US), Abbott Laboratories (US), Boston Scientific (US), LivaNova (GB), JenaValve Technology (DE), CryoLife (US), Sorin Group (IT), AtriCure (US)

Our Impact

Enabled $4.3B Revenue Impact for Fortune 500 and Leading Multinationals

Partnering with 2000+ Global Organizations Each Year

30K+ Citations by Top-Tier Firms in the Industry

Heart Valves Market Trends

The Heart Valves Market is currently experiencing a transformative phase, driven by advancements in technology and an increasing prevalence of cardiovascular diseases. Innovations in materials and design are enhancing the performance and longevity of heart valves, which appears to be a key factor in attracting both healthcare providers and patients. Furthermore, the growing awareness of heart health and the importance of timely interventions is likely to propel demand for these medical devices.

As the population ages, the need for effective heart valve solutions is becoming more pronounced, suggesting a robust growth trajectory for the market. In addition to technological advancements, regulatory frameworks are evolving to facilitate faster approvals for new heart valve products. This shift may encourage manufacturers to invest in research and development, potentially leading to a wider array of options for patients.

Moreover, the rise of minimally invasive procedures is reshaping the landscape of the Heart Valves Market, as these techniques often result in shorter recovery times and improved patient outcomes. Overall, the market appears poised for significant expansion, driven by a combination of innovation, regulatory support, and changing patient preferences.

Technological Advancements

The Heart Valves Market is witnessing rapid technological innovations, particularly in the development of bioprosthetic and transcatheter heart valves. These advancements are enhancing the durability and functionality of heart valves, which may lead to improved patient outcomes and satisfaction.

Regulatory Changes

Evolving regulatory frameworks are streamlining the approval processes for new heart valve products. This trend could encourage manufacturers to accelerate their research and development efforts, resulting in a broader range of options available to healthcare providers and patients.

Minimally Invasive Procedures

The increasing preference for minimally invasive surgical techniques is reshaping the Heart Valves Market. These procedures often offer reduced recovery times and lower risks, making them more appealing to both patients and healthcare professionals.

Heart Valves Market Drivers

Aging Population

The increasing prevalence of heart valve diseases among the aging population appears to be a primary driver for the Heart Valves Market. As individuals age, the risk of developing conditions such as aortic stenosis and mitral regurgitation escalates. According to recent data, nearly 30% of individuals over the age of 70 are affected by some form of heart valve disease.

This demographic shift necessitates a greater demand for heart valve interventions, thereby propelling the market forward. The Heart Valves Market is likely to experience substantial growth as healthcare systems adapt to meet the needs of this expanding patient population, emphasizing the importance of innovative treatment options and advanced surgical techniques.

Technological Innovations

Technological advancements in heart valve design and surgical techniques are significantly influencing the Heart Valves Market. Innovations such as transcatheter aortic valve replacement (TAVR) and the development of bioprosthetic valves have revolutionized treatment options. The market for heart valves is projected to reach USD 12 billion by 2026, driven by these advancements.

Furthermore, the integration of 3D printing technology in valve manufacturing allows for personalized solutions tailored to individual patient anatomies. This trend not only enhances patient outcomes but also fosters competition among manufacturers, leading to a broader range of products in the Heart Valves Market. As technology continues to evolve, it is anticipated that the market will expand further, offering new possibilities for both patients and healthcare providers.

Increased Awareness and Screening

Growing awareness regarding heart health and the importance of early screening for heart valve diseases is contributing to the expansion of the Heart Valves Market. Educational campaigns and initiatives by healthcare organizations are encouraging individuals to seek medical advice and undergo regular check-ups. This proactive approach is leading to earlier diagnoses and, consequently, a higher demand for heart valve interventions.

The Heart Valves Market is likely to benefit from this trend, as more patients are identified as candidates for surgical procedures. Furthermore, advancements in diagnostic technologies, such as echocardiography, are facilitating timely detection of valve disorders, further driving the market's growth. As awareness continues to rise, the industry may witness a surge in both preventive and corrective heart valve treatments.

Rising Incidence of Cardiovascular Diseases

The escalating incidence of cardiovascular diseases is a critical factor propelling the Heart Valves Market. Heart valve disorders are often associated with other cardiovascular conditions, which are on the rise due to lifestyle changes and an increase in risk factors such as obesity and diabetes.

Recent statistics indicate that cardiovascular diseases account for approximately 31% of all global deaths, underscoring the urgent need for effective treatment options. This alarming trend is likely to drive demand for heart valve replacements and repairs, thereby stimulating growth within the Heart Valves Market. As healthcare providers seek to address this public health challenge, the focus on innovative heart valve solutions is expected to intensify.

Regulatory Support and Reimbursement Policies

Supportive regulatory frameworks and favorable reimbursement policies are essential drivers for the Heart Valves Market. Governments and health authorities are increasingly recognizing the importance of heart valve interventions in improving patient outcomes. As a result, there has been a push for streamlined approval processes for new heart valve technologies, which encourages innovation and market entry.

Additionally, favorable reimbursement policies for heart valve procedures are likely to enhance patient access to these treatments, thereby stimulating demand. The Heart Valves Market stands to gain from these supportive measures, as they not only facilitate the introduction of advanced products but also ensure that patients receive necessary care without financial barriers. This regulatory environment is expected to foster a more robust market landscape.

Market Segment Insights

By Application: Aortic Valve Repair (Largest) vs. Mitral Valve Repair (Fastest-Growing)

In the Heart Valves Market, the application segment is characterized by distinct segments such as Aortic Valve Repair, Mitral Valve Repair, and Tricuspid Valve Repair. Currently, Aortic Valve Repair holds a significant share of the market, being the most widely performed procedure due to the increasing prevalence of aortic stenosis in aging populations. Conversely, the Mitral Valve Repair segment is rapidly gaining traction, illustrating a marked increase in demand as improvements in surgical techniques enhance patient outcomes.

Aortic Valve Repair (Dominant) vs. Mitral Valve Repair (Emerging)

The Aortic Valve Repair segment remains dominant within the market share, driven by heightened awareness and diagnosis of aortic valve disorders. This procedure is pivotal for patients with critical aortic conditions, leading to enhanced survival rates. In contrast, Mitral Valve Repair is emerging as a significant contender, fueled by advancements in minimally invasive techniques and a growing recognition of mitral valve diseases. The market is witnessing an uptick in procedures performed, particularly with the introduction of innovative repair devices that have improved surgical efficacy and recovery times. These trends indicate a dynamic competitive landscape where Aortic Valve Repair continues to lead, while Mitral Valve Repair is on the rise.

By Type: Mechanical Valves (Largest) vs. Bioprosthetic Valves (Fastest-Growing)

In the Heart Valves Market, the distribution of market share among the different types of valves is notably significant. Mechanical valves currently hold the largest share, favored for their durability and long lifespan, making them a reliable choice for many patients. In contrast, bioprosthetic valves are rapidly gaining traction, offering advantages such as biocompatibility and reduced anticoagulation therapy, thereby appealing to an increasing number of clinicians and patients alike.

Mechanical Valves (Dominant) vs. Bioprosthetic Valves (Emerging)

Mechanical valves are characterized by their robust construction and longevity, making them a dominant choice among cardiac surgeons. They are particularly suitable for younger patients requiring valve replacement, as they can last for decades. However, their requirement for lifelong anticoagulation therapy is a limiting factor. On the other hand, bioprosthetic valves are emerging as a popular alternative due to their natural tissue composition, which minimizes the risk of thrombosis and eliminates the need for intensive anticoagulation. This trend highlights an evolving preference towards more patient-friendly options in valve replacement therapies.

By End Use: Hospital (Largest) vs. Ambulatory Surgical Centers (Fastest-Growing)

The heart valves market showcases significant variability across different end-use segments, with hospitals accounting for the largest share. These medical institutions primarily focus on high-risk surgical procedures and complex cardiac interventions, driving the demand for advanced valve solutions. The market dynamics indicate that hospitals remain the primary setting for heart valve surgeries, reinforcing their dominant position in the segment. In contrast, ambulatory surgical centers are emerging rapidly, driven by innovations in minimally invasive procedures that enable quicker patient recovery and shorter hospital stays. This segment is experiencing growth from an increase in outpatient surgeries and a shift toward value-based healthcare, with patients and providers seeking efficient, cost-effective treatment options.

Hospital (Dominant) vs. Ambulatory Surgical Centers (Emerging)

In the market share, hospitals are regarded as the dominant end-use segment due to their comprehensive infrastructure and specialized cardiology departments that cater to complex cardiac surgeries. They have established protocols for valve replacement and repair, utilizing advanced technologies to improve surgical outcomes. On the other hand, ambulatory surgical centers represent an emerging segment where a growing number of heart valve procedures are performed on an outpatient basis. These centers typically offer lower costs and improved recovery times for patients, making them increasingly popular. The drive towards outpatient care is supported by advancements in surgical techniques and patient management, positioning ambulatory surgical centers as a key area of growth for the heart valves market.

By Material: Biological Tissue (Largest) vs. Synthetic Polymer (Fastest-Growing)

In the Heart Valves Market, the material segment is diverse, comprising biological tissue, synthetic polymer, and metallic alloys. Biological tissue valves currently dominate the market, reflecting a preference for biocompatibility and natural functionality. Synthetic polymers, while smaller in share, are gaining attention due to their adaptability and durability. The metallic alloys segment, though traditionally significant, showcases a slower growth compared to the others, largely owing to advancements in bioengineered alternatives.

Biological Tissue (Dominant) vs. Synthetic Polymer (Emerging)

Biological tissue valves are the dominant choice among heart valve materials, as they offer a significant advantage in terms of patient compatibility and mimicry of natural tissue properties. Their growing acceptance is driven by the aging population and a rise in heart diseases, necessitating effective treatment options. On the other hand, synthetic polymers are emerging as a noteworthy contender, providing benefits such as lower thrombogenicity and the ability to customize designs for specific patient needs. They are particularly favored in minimally invasive surgical procedures, presenting opportunities for innovation and expansion in the market.

Get more detailed insights about Heart Valves Market

Request Free Sample

Regional Insights

North America : Market Leader in Innovation

North America leads in the Heart Valves Market Size, accounting for over 45% of the global revenue in 2024. The region's growth is driven by advanced healthcare infrastructure, increasing prevalence of cardiovascular diseases, and a strong focus on research and development. Regulatory support from agencies like the FDA has accelerated the approval of innovative heart valve technologies, enhancing patient access to cutting-edge treatments.

The United States is the primary contributor to this market, with key players such as Edwards Lifesciences, Medtronic, and Abbott Laboratories leading the competitive landscape. The presence of these major companies fosters innovation and competition, ensuring a steady supply of advanced heart valve solutions. Additionally, the growing trend of minimally invasive procedures is further propelling market growth in this region.

Europe : Emerging Regulatory Frameworks

Europe Heart Valves Market was valued at USD 2.7 billion in 2024, making it the second-largest regional market with a 30% share.The region's growth is fueled by an aging population, increasing awareness of heart diseases, and supportive regulatory frameworks. The European Medicines Agency (EMA) has been instrumental in streamlining the approval process for new heart valve technologies, which has encouraged innovation and market entry of advanced products.

Leading countries in this market include Germany, France, and the UK, where companies like JenaValve Technology and LivaNova are prominent. The competitive landscape is characterized by a mix of established players and emerging startups, all striving to meet the growing demand for effective heart valve solutions. The emphasis on patient-centric designs and minimally invasive techniques is shaping the future of the heart valves market in Europe.

Asia-Pacific : Rapidly Growing Market Potential

Asia-Pacific is witnessing rapid growth in the heart valves market, accounting for approximately 20% of the global share. The region's expansion is driven by increasing healthcare expenditure, rising awareness of cardiovascular diseases, and a growing elderly population. Countries like China and India are investing heavily in healthcare infrastructure, which is expected to further boost the demand for heart valve products in the coming years.

China is the largest market in the region, with significant contributions from local manufacturers and international players. The competitive landscape is evolving, with companies like Medtronic and Abbott Laboratories expanding their presence. The focus on affordable healthcare solutions and the adoption of advanced technologies are key trends shaping the heart valves market in Asia-Pacific, making it a promising area for future growth.

Middle East and Africa : Untapped Market Opportunities

The Middle East and Africa region is gradually emerging in the heart valves market, holding about 5% of the global share. The growth is primarily driven by increasing healthcare investments, rising prevalence of heart diseases, and a growing awareness of advanced medical technologies. Governments in countries like South Africa and the UAE are implementing policies to improve healthcare access, which is expected to enhance market growth in the coming years.

South Africa is the leading market in this region, with a growing number of healthcare facilities adopting advanced heart valve technologies. The competitive landscape is characterized by a mix of local and international players, including Boston Scientific and CryoLife. The focus on improving healthcare infrastructure and increasing patient access to innovative treatments is shaping the future of the heart valves market in the Middle East and Africa.

Key Players and Competitive Insights

The Heart Valves Market is currently characterized by a dynamic competitive landscape, driven by technological advancements, increasing prevalence of cardiovascular diseases, and a growing aging population. Major players such as Edwards Lifesciences (US), Medtronic (US), and Abbott Laboratories (US) are at the forefront, each adopting distinct strategies to enhance their market positioning. Edwards Lifesciences (US) focuses on innovation in transcatheter heart valves, while Medtronic (US) emphasizes a broad portfolio that includes both surgical and transcatheter solutions.

Abbott Laboratories (US) is leveraging its expertise in minimally invasive procedures to capture a larger market share, indicating a trend towards less invasive treatment options across the industry. The business tactics employed by these companies reflect a concerted effort to optimize supply chains and localize manufacturing. The Heart Valves Market appears moderately fragmented, with a mix of established players and emerging companies. This fragmentation allows for diverse product offerings and competitive pricing strategies, although the influence of key players remains substantial.

The collective actions of these companies shape a competitive environment that is increasingly focused on technological innovation and patient-centric solutions. In August 2025, Edwards Lifesciences (US) announced the launch of its next-generation transcatheter aortic valve replacement (TAVR) system, which is designed to improve patient outcomes through enhanced delivery mechanisms. This strategic move not only reinforces Edwards' commitment to innovation but also positions the company to capture a larger share of the growing TAVR market, which is expected to expand significantly in the coming years.

The introduction of this advanced system may also compel competitors to accelerate their own product development timelines. In September 2025, Medtronic (US) revealed a partnership with a leading digital health company to integrate AI-driven analytics into its heart valve monitoring systems. This collaboration aims to enhance patient monitoring and outcomes through real-time data analysis.

By embracing digital transformation, Medtronic is likely to improve its competitive edge, as the integration of AI into healthcare solutions is becoming increasingly vital for patient management and operational efficiency. In July 2025, Abbott Laboratories (US) expanded its manufacturing capabilities in Europe to meet the rising demand for its heart valve products. This strategic expansion not only enhances Abbott's supply chain reliability but also positions the company to respond more effectively to regional market needs.

Such moves indicate a broader trend among key players to localize production, thereby reducing lead times and improving service delivery. As of October 2025, the Heart Valves Market is witnessing trends that emphasize digitalization, sustainability, and the integration of artificial intelligence. Strategic alliances are becoming increasingly important, as companies seek to leverage complementary strengths to enhance their product offerings.

The competitive differentiation is likely to evolve from traditional price-based competition towards a focus on innovation, technological advancements, and supply chain reliability, suggesting that companies that prioritize these areas will be better positioned for future success.

Key Companies in the Heart Valves Market include

Industry Developments

There have been a number of important changes in the Heart Valves Market in the last few months. Medtronic released a new transcatheter aortic valve replacement (TAVR) device in September 2023. The goal of this device is to give patients with severe aortic stenosis more treatment options. Edwards Lifesciences, on the other hand, said that its sales grew a lot in the third quarter of 2023.

This was because more people around the world wanted its heart valve products, especially in the U.S. market. JenaValve Technology kept making moves to strengthen its position in the transcatheter valve market, but there were no confirmed acquisitions in August 2023. There are reports that it bought Cardiothoracic Systems, but these reports seem to be false and out of date. Guidant and then Boston Scientific bought Cardiothoracic Systems in the early 2000s.

As of March 2023, there is no public record of a partnership between LivaNova and Boston Scientific. However, both companies are still working on their own advanced cardiac solutions. Their continued investments in research and development show that the structural heart technology industry is moving toward more innovation.

The Heart Valves Market is expected to grow a lot by the middle of 2023. This is because cardiovascular diseases are becoming more common, populations are getting older, and valve replacement and repair techniques are always getting better. Agencies like the FDA and EMA are helping to promote innovation, making it easier for people to access new treatments and products. The heart valves segment is in a good place for strong and long-term growth because established companies are pushing technology forward and new companies are entering the market.

Future Outlook

Heart Valves Market Future Outlook

The Heart Valves Market size is projected to reach USD 32.25 Billion by 2035, growing at a CAGR of 12.2%, driven by technological advancements, increasing prevalence of heart diseases, and rising healthcare expenditure.

New opportunities lie in:

Development of biodegradable heart valves for enhanced patient outcomes. Expansion of telehealth services for remote monitoring of valve patients. Investment in AI-driven predictive analytics for personalized valve treatment plans.

By 2035, the Heart Valves Market is expected to achieve substantial growth, reflecting evolving healthcare demands.

Market Segmentation

Heart Valves Market Type Outlook

Mechanical Valves
Bioprosthetic Valves
Transcatheter Valves

Heart Valves Market End Use Outlook

Hospital
Ambulatory Surgical Centers
Cardiac Clinics

Heart Valves Market Material Outlook

Biological Tissue
Synthetic Polymer
Metallic Alloys

Heart Valves Market Application Outlook

Aortic Valve Repair
Mitral Valve Repair
Tricuspid Valve Repair

Report Scope

MARKET SIZE 2024	9.088(USD Billion)
MARKET SIZE 2025	10.2(USD Billion)
MARKET SIZE 2035	32.25(USD Billion)
COMPOUND ANNUAL GROWTH RATE (CAGR)	12.2% (2025 - 2035)
REPORT COVERAGE	Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
BASE YEAR	2024
Market Forecast Period	2025 - 2035
Historical Data	2019 - 2024
Market Forecast Units	USD Billion
Key Companies Profiled	Edwards Lifesciences (US), Medtronic (US), Abbott Laboratories (US), Boston Scientific (US), LivaNova (GB), JenaValve Technology (DE), CryoLife (US), Sorin Group (IT), AtriCure (US)
Segments Covered	Applications, Types, End Use, Material, Regional
Key Market Opportunities	Advancements in minimally invasive techniques enhance patient outcomes in the Heart Valves Market.
Key Market Dynamics	Technological advancements and regulatory changes drive innovation and competition in the heart valves market.
Countries Covered	North America, Europe, APAC, South America, MEA

Market Highlights

Heart Valves Companies

FAQs

What is the current valuation of the Heart Valves Market as of 2024?

The Heart Valves Market was valued at 9.088 USD Billion in 2024.

What is the projected market size for the Heart Valves Market in 2035?

The market is projected to reach 32.25 USD Billion by 2035.

What is the expected CAGR for the Heart Valves Market during the forecast period 2025 - 2035?

The expected CAGR for the Heart Valves Market during 2025 - 2035 is 12.2%.

Which companies are considered key players in the Heart Valves Market?

Key players include Edwards Lifesciences, Medtronic, Abbott Laboratories, and Boston Scientific.

What are the main application segments in the Heart Valves Market?

The main application segments include Aortic Valve Repair, Mitral Valve Repair, and Tricuspid Valve Repair.

How does the market for Mechanical Valves compare to Bioprosthetic Valves?

The market for Mechanical Valves is projected to grow from 3.5 to 12.5 USD Billion, while Bioprosthetic Valves are expected to grow from 2.5 to 9.5 USD Billion.

What are the anticipated growth figures for the Ambulatory Surgical Centers segment?

The Ambulatory Surgical Centers segment is expected to grow from 2.5 to 9.0 USD Billion.

What materials are primarily used in the Heart Valves Market?

The primary materials include Biological Tissue, Synthetic Polymer, and Metallic Alloys.

What is the projected growth for the Tricuspid Valve Repair segment?

The Tricuspid Valve Repair segment is projected to grow from 3.088 to 10.25 USD Billion.

How does the market for Transcatheter Valves compare to other valve types?

The market for Transcatheter Valves is expected to grow from 3.088 to 10.25 USD Billion, indicating robust demand.

Author

Author

Rahul Gotadki

Research Manager

He holds an experience of about 9+ years in Market Research and Business Consulting, working under the spectrum of Life Sciences and Healthcare domains. Rahul conceptualizes and implements a scalable business strategy and provides strategic leadership to the clients. His expertise lies in market estimation, competitive intelligence, pipeline analysis, customer assessment, etc.

Get In Touch

Leave a Comment

Certified Researchers

Customize Report

Research Approach

Secondary Research

The secondary research process involved comprehensive analysis of regulatory databases, peer-reviewed cardiovascular journals, clinical publications, and authoritative health organizations. Key sources included the US Food & Drug Administration (FDA) Center for Devices and Radiological Health (CDRH), European Medicines Agency (EMA) Medical Device Coordination Group (MDCG), International Organization for Standardization (ISO) 14155 (Clinical Investigation of Medical Devices), Society of Thoracic Surgeons (STS), American College of Cardiology (ACC), American Heart Association (AHA), European Association for Cardio-Thoracic Surgery (EACTS), European Society of Cardiology (ESC), National Institutes of Health (NIH) National Heart, Lung, and Blood Institute (NHLBI), National Center for Biotechnology Information (NCBI/PubMed), CDC National Center for Health Statistics (NCHS), World Health Organization (WHO) Cardiovascular Disease Database, EU Eurostat Healthcare Statistics, and national cardiovascular registries from key markets including the National Cardiovascular Data Registry (NCDR) in the US and the UK Central Cardiac Audit Database (CCAD). These sources were used to collect procedure statistics (TAVR, SAVR, mitral valve repair volumes), regulatory approval data (PMA, 510(k), CE Mark), clinical safety studies (major adverse cardiac events, valve durability data), demographic trends (aging population, valvular heart disease prevalence), and competitive landscape analysis for mechanical valves, bioprosthetic tissue valves, transcatheter heart valves (THV), and emerging polymer-based valve technologies.

Primary Research

In order to gather both qualitative and quantitative insights, supply-side and demand-side stakeholders were interviewed during the primary research process. CEOs, VPs of R&D, chiefs of regulatory affairs, and commercial directors from OEM component suppliers and heart valve manufacturers were examples of supply-side sources. Board-certified cardiothoracic surgeons, interventional cardiologists, directors of cardiac catheterization laboratories, and procurement leads from academic medical centers, community hospitals, ambulatory surgery centers, and specialty cardiac clinics were among the demand-side sources. Primary research verified product pipeline timelines (next-generation TAVR, polymer valves, annuloplasty rings), validated market segmentation across valve types (mechanical, bioprosthetic, transcatheter), and obtained information on clinical adoption patterns (transition from surgical to transcatheter approaches), pricing strategies (valve-in-valve procedures, bundled payments), and reimbursement dynamics (CMS coverage decisions, DRG classifications).

Primary Respondent Breakdown:

By Designation: C-level Primaries (32%), Director Level (30%), Others (38%)

By Region: North America (38%), Europe (25%), Asia-Pacific (28%), Rest of World (9%)

Market Size Estimation

Global market valuation was derived through revenue mapping and procedure volume analysis. The methodology included:

Identification of 40+ key manufacturers across North America, Europe, Asia-Pacific, and Latin America (Edwards Lifesciences, Medtronic, Abbott, Boston Scientific, LivaNova, CryoLife, JenaValve Technology, Sorin Group)

Product mapping across mechanical heart valves (bileaflet, tilting disc), bioprosthetic tissue valves (bovine pericardial, porcine aortic), transcatheter valves (TAVR, TMVR, TTVR), and annuloplasty repair products

Analysis of reported and modeled annual revenues specific to heart valve portfolios (surgical valves, transcatheter valves, repair accessories)

Coverage of manufacturers representing 75-80% of global market share in 2024

Extrapolation using bottom-up (procedure volume × ASP by country/region, accounting for hospital vs. ASC settings) and top-down (manufacturer revenue validation, supply chain verification) approaches to derive segment-specific valuations across aortic valve repair, mitral valve repair, and tricuspid valve repair applications